Controlling cardiovascular risk factors and maintaining long-term disease remission mitigated the increased risk for ...

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) ...

"Incomplete lupus" is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...

The presence of antiarrestin autoantibodies among patients with SLE is associated with an increased risk of developing HCQ-related retinal toxicity.

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found ...

“Living alone, I rely on my parents and friends to help with daily tasks during flares,” she shares. “This experience has ...

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

Atherosclerosis progression was more than twice as common in younger people with systemic lupus erythematosus (SLE) than in ...

The increased risks for arterial thrombotic events (ATE), venous thromboembolism (VTE), and all-cause mortality known to be found among patients with systemic lupus erythematosus (SLE) were validated ...

ALM-223 is under development for the treatment of systemic lupus erythematosus (SLE) and atopic dermatitis (AD). It is administered through subcutaneous route in the form of liquid. It is a fusion ...

The prevalence of fibromyalgia is higher among patients with SLE vs the general population, adding to an already significant ...